Korean J Crit Care Med.  2015 Nov;30(4):272-279. 10.4266/kjccm.2015.30.4.272.

Dexmedetomidine Use in Patients with 33degrees C Targeted Temperature Management: Focus on Bradycardia as an Adverse Effect

Affiliations
  • 1Department of Emergency Medicine, Ajou University School of Medicine, Suwon, Korea. avenue59@ajou.ac.kr

Abstract

BACKGROUND
This study aimed to investigate bradycardia as an adverse effect after administration of dexmedetomidine during 33degrees C target temperature management.
METHODS
A retrospective study was conducted on patients who underwent 33degrees C target temperature management in the emergency department during a 49-month study period. We collected data including age, sex, weight, diagnosis, bradycardia occurrence, target temperature management duration, sedative drug, and several clinical and laboratory results. We conducted logistic regression for an analysis of factors associated with bradycardia.
RESULTS
A total of 68 patients were selected. Among them, 39 (57.4%) showed bradycardia, and 56 (82.4%) were treated with dexmedetomidine. The odds ratio for bradycardia in the carbon monoxide poisoning group compared to the cardiac arrest group and in patients with higher body weight were 7.448 (95% confidence interval [CI] 1.834-30.244, p = 0.005) and 1.058 (95% CI 1.002-1.123, p = 0.044), respectively. In the bradycardia with dexmedetomidine group, the infusion rate of dexmedetomidine was 0.41 +/- 0.15 microg/kg/h. Decisions of charged doctor's were 1) slowing infusion rate and 2) stopping infusion or administering atropine for bradycardia. No cases required cardiac pacing or worsened to asystole.
CONCLUSIONS
Despite the frequent occurrence of bradycardia after administration of dexmedetomidine during 33degrees C target temperature management, bradycardia was completely recovered after reducing infusion rate or stopping infusion. However, reducing the infusion rate of dexmedetomidine lower than the standard maintenance dose could be necessary to prevent bradycardia from developing in patients with higher body weight or carbon monoxide poisoning during 33degrees C targeted temperature management.

Keyword

adverse effects; bradycardia; dexmedetomidine; hypothermia, induced

MeSH Terms

Atropine
Body Weight
Bradycardia*
Carbon Monoxide Poisoning
Dexmedetomidine*
Diagnosis
Emergency Service, Hospital
Heart Arrest
Humans
Hypothermia, Induced
Logistic Models
Odds Ratio
Retrospective Studies
Atropine
Dexmedetomidine

Reference

References

1. Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013; 41:263–306.
Article
2. Reade MC, Finfer S. Sedation and delirium in the intensive care unit. N Engl J Med. 2014; 370:444–54.
Article
3. Fraser GL, Devlin JW, Worby CP, Alhazzani W, Barr J, Dasta JF, et al. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013; 41(9 Suppl 1):S30–8.
4. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JANA. 2009; 301:489–99.
5. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004; 30:2188–96.
6. Patel SB, Kress JP. Sedation and analgesia in the mechanically ventilated patient. Am J Respir Crit Care Med. 2012; 185:486–97.
Article
7. Ma D, Rajakumaraswamy N, Maze M. alpha2-Adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull. 2005; 71:77–92.
8. Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010; 36:926–39.
Article
9. Holliday SF, Kane-Gill SL, Empey PE, Buckley MS, Smithburger PL. Interpatient variability in dexmedetomidine response: a survey of the literature. ScientificWorldJournal. 2014; 2014:805013.
Article
10. Yu SB. Dexmedetomidine sedation in ICU. Korean J Anesthesiol. 2012; 62:405–11.
Article
11. Iirola T, Ihmsen H, Laitio R, Kentala E, Aantaa R, Kurvinen JP, et al. Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Br J Anaesth. 2012; 108:460–8.
Article
12. Zhou J, Poloyac SM. The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol. 2011; 7:803–16.
Article
13. Zhou J, Empey PE, Bies RR, Kochanek PM, Poloyac SM. Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. Drug Metab Dispos. 2011; 39:2209–18.
Article
14. Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med. 2007; 35:2196–204.
Article
15. Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med. 2009; 37:1101–20.
Article
16. Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009; 37(7 Suppl):S186–202.
Article
17. Hong JH, Jeong JH, Chang JY, Yeo MJ, Jeong HY, Bae HJ, et al. Repeated hypothermia for rebound cerebral edema after therapeutic hypothermia in malignant cerebral infarction. Korean J Crit Care Med. 2013; 28:221–4.
Article
18. Chang JY, Hong JH, Jeong JH, Nam S-J, Jang JH, Bang JS, et al. Therapeutic hypothermia after decompressive craniectomy in malignant cerebral infarction. Korean J Crit Care Med. 2014; 29:93–8.
Article
19. Lee YH, Sohn YD, Park SM, Lee WW, Ahn JY, Ahn HC. Treatment of carbon monoxide poisoning with therapeutic hypothermia. Korean J Crit Care Med. 2013; 28:218–20.
Article
20. Ezzati M, Broad K, Kawano G, Faulkner S, Hassell J, Fleiss B, et al. Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model. Acta Anaesthesiol Scand. 2014; 58:733–42.
Article
21. Park EJ, Min YG, Kim GW, Cho JP, Maeng WJ, Choi SC. Pathophysiology of brain injuries in acute carbon monoxide poisoning: a novel hypothesis. Med Hypotheses. 2014; 83:186–9.
Article
22. Jung YS, Lee JS, Min YG, Park JS, Jeon WC, Park EJ, et al. Carbon monoxide-induced cardiomyopathy. Circ J. 2014; 78:1437–44.
Article
23. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, Böttiger BW, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation. 2008; 118:2452–83.
24. Rivers EP, Wortsman J, Rady MY, Blake HC, McGeorge FT, Buderer NM. The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. Chest. 1994; 106:1499–507.
Article
25. Alonso JR, Cardellach F, López S, Casademont J, Miró O. Carbon monoxide specifically inhibits cytochrome c oxidase of human mitochondrial respiratory chain. Pharmacol Toxicol. 2003; 93:142–6.
Article
26. Tobias JD. Bradycardia during dexmedetomidine and therapeutic hypothermia. J Intensive Care Med. 2008; 23:403–8.
Article
27. Gerlach AT, Dasta JF, Steinberg S, Martin LC, Cook CH. A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients. J Crit Care. 2009; 24:568–74.
Article
Full Text Links
  • KJCCM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr